Specialized Pediatric Immunotherapy
Welcome to our Specialized Pediatric Immunotherapy section, where we focus on advanced treatment options for children and infants with severe respiratory and immunological conditions. This category includes life-enhancing therapies such as Xolair, an injection for children over twelve with moderate to severe persistent asthma poorly controlled by inhaled corticosteroids, and Synagis, a monthly injection recommended for infants born prematurely or with chronic lung disease or congenital heart disease. Our goal is to provide comprehensive information and support to families navigating these critical treatments.
XOLAIR
Xolair is an injection for children over twelve with moderate to severe asthma not controlled by inhaled corticosteroids. Administered based on weight, it is given every 2 weeks or monthly, depending on the dosage. Eligibility requires allergy testing and bloodwork to check IgE levels.
For more information, visit the XOLAIR site here.
SYNAGIS
Synagis is a monthly injection for infants born before 35 weeks or with chronic lung disease or congenital heart disease. Insurance or Medicaid must authorize Synagis, requiring a NICU discharge summary and recent weight. Due to high costs, injections are only given with proper authorization. Coverage is now often limited to infants born before 29 weeks or with severe conditions, for up to 5 doses. If denied, AstraZeneca offers a free program for eligible families. More info is available at www.azandmeapp.com.
For more information, visit the SYNAGIS site here.